Interestingly, BAG3 levels also decline in advanced HF, suggesting that reduced BAG3 expression is a common pathway in both genetic and non-genetic forms of DCM, marking BAG3 as a particularly intriguing therapeutic target [151]. Here, BAG3 is linked to familial dilated cardiomyopathy.